Azithromycin treatment follow-up: Antibacterial susceptibility of Chlamydia trachomatis in patients with chronic prostatitis

International Journal of Antimicrobial Agents

Volumn 23, Issue SUPPL. 1, 2004, Pages 79-82

  Smelov, V ^a,c,d   Krylova, T ^b   Smelova, N ^c   Norman, L ^b  

^a ST PETERSBURG STATE UNIVERSITY   (Russian Federation)

^b PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^c City Sport Medical Center   (Russian Federation)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Azithromycin; Chlamydia trachomatis; Chronic prostatitis; Persistence

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; JOSAMYCIN; LOMEFLOXACIN; MIDECAMYCIN; OFLOXACIN; PEFLOXACIN; RIFAMPICIN; ROXITHROMYCIN; SPIRAMYCIN;

ADULT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIUM ISOLATION; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CHRONIC PROSTATITIS; CONFERENCE PAPER; CONTROLLED STUDY; FOLLOW UP; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; SINGLE DRUG DOSE;

EID: 1642396533     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2003.09.001     Document Type: Conference Paper

References (24)

1. Naber KG, Bergman B, Bishop MC, Bjerklund-Johansen TE, Botto H, Lobel B, et al. Prostatitis, epididymitis and orchitis. In: EAU guidelines on urinary and male genital tract infection. Arhnem: Drukkerij Gelderland bv; 2001.
2. Centers for Disease Control. Sexually Transmitted Diseases Treatment Guidelines. 2002;51:32-6.
3. Katz BP, Fortenberry D, Orr D. Factors affecting chlamydial persistence or recurrence one and three months after treatment. In: Stephens RS, Byrne GI, Christiansen G, et al., editors. Chlamydia Infections: Proceedings of the Ninth International Symposium on Human Infection, Napa, Berkeley, CA: Berkeley University Press, 1998. p. 35-8.
4. Bragina E.Y., Gomberg M.A., Dmitriev G.A. Electron microscopic evidence of persistent chlamydial infection following treatment. J Eur Acad Dermatol Venereol. 15:2001;405-409.
5. Lietman T., Porco T., Dawson C., Blower S. Global elimination of trachoma: how frequently should we administer mass chemotherapy? Nat Med. 5:1999;572-576.
6. Somani J., Bhullar V.B., Workowski K.A., Farshy C.E., Black C.M. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis. 181:2000;1421-1427.
7. Dreses-Werringloer U., Padubrin I., Zeidler H., Kohler L. Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro. Antimicrob Agents Chemother. 45:2001;3001-3008.
8. Rice R.J., Bhullar V., Mitchell S.H., Bullard J., Knapp J.S. Susceptibilities of Chlamydia trachomatis isolates causing uncomplicated female genital tract infections and pelvic inflammatory disease. Antimicrob Agents Chemother. 39:1995;760-762.
9. Notomi T., Ikeda Y., Nagayama A. Minimum inhibitory and minimal lethal concentration against Chlamydia trachomatis dependent on the time of addition and the duration of the presence of antibiotics. Chemotherapy. 45:1999;242-248.
10. Lefevre J.C., Courdil M., Lareng M.B. In vitro evaluation of activities of azithromycin. Pathol Biol Paris. 41:1993;313-315.
11. Samra Z., Rosenberg S., Soffer Y., Dan M. In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines. Diagn Microbiol Infect Dis. 39:2001;177-179.
12. Weidner W., Diemer Th., Huwe P., Rainer H., Ludwig M. The role of Chlamydia trachomatis in prostatitis. Int J Antimicrob Agents. 19:2002;466-470.
13. Jones R.B., Van der Pol B., Martin D.H., Shepard M.K. Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics. J Infect Dis. 162:1990;1309-1315.
14. Lefevre J.C., Lepargneur J.P. Comparative in vitro susceptibility of a tetracycline-resistant Chlamydia trachomatis strain isolated in Toulouse (France). Sex Transm Dis. 25:1998;350-352.
15. Stamm W.E. Potential for antimicrobial resistance in Chlamydia pneumoniae. J Infect Dis. 181:2000;456-459.
16. Workowski K.A., Lampe M.F., Wong K.G., Watts M.B., Stamm W.E. Long-term eradication of Chlamydia trachomatis genital infection after antimicrobial therapy. Evidence against persistent infection. JAMA. 270:1993;2071-2075.
17. Bjerklund Johansen T.E., Gruneberg R.N., Guibert J., Hofstetter A., Lobel B., Naber K.G.et al. The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Eur Urol. 34:1998;457-466.
18. Stamm WE. Chlamydia trachomatis infections of the adult. In: Holmes KK, Mardh PA, Sparling PF, et al., editors. Sexually Transmitted Diseases. 3rd ed. New York: McGraw-Hill; 1999. p. 407-22.
19. Dessus-Babus S., Bebear C.M., Charron A., Bebear C., de Barbeyrac B. Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained in vitro. Antimicrob Agents Chemother. 42:1998;2474-2481.
20. Dreses-Werringloer U., Padubrin I., Jurgens-Saathoff B., Hudson A.P., Zeidler H., Kohler L. Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro. Antimicrob Agents Chemother. 44:2000;3288-3297.
21. Morrissey I., Salman H., Bakker S., Farrell D., Bebear C.M., Ridgway G. Serial passage of Chlamydia spp. in sub-inhibitory fluoroquinolone concentrations. J Antimicrob Chemother. 49:2002;757-761.
22. Nickel JC. Prostatitis: Evolving management strategies. In: Carson CC, guest editor. The Urologic Clinics of North America. London: Saunders; 1999.
23. Dean D., Suchland R.J., Stamm W.E. Evidence for long-term cervical persistence of Chlamydia trachomatis by omp1 genotyping. J Infect Dis. 182:2000;909-916.
24. Weiss E. The effect of antibiotics on agents of the psittacosis- lymphogranuloma group. J Infect. 87:1950;249-263.